Exelixis to Release Third Quarter 2025 Financial Results on Tuesday, November 4, 2025Business Wire • 10/21/25
Exelixis Announces Detailed Results from Phase 3 STELLAR-303 Pivotal Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer Presented at ESMO 2025 and Published in The LancetBusiness Wire • 10/20/25
Exelixis Announces Results from Subgroup Analysis of CABINET Phase 3 Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Advanced Lung and Thymic Neuroendocrine Tumors at ESMO 2025Business Wire • 10/18/25
Prediction: These 2 Under-the-Radar Stocks Could Beat the Market in the Next 5 YearsThe Motley Fool • 09/30/25
Exelixis, Inc. (EXEL) Presents at Bernstein 2nd Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/24/25
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXELGlobeNewsWire • 09/10/25
Exelixis, Inc. (EXEL) Presents At H.C. Wainwright 27th Annual Global Investment Conference TranscriptSeeking Alpha • 09/10/25
Exelixis, Inc. (EXEL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/09/25
EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with the Schall Law FirmPRNewsWire • 09/04/25
Exelixis, Inc. (EXEL) Presents At Citi's Biopharma Back To School Conference TranscriptSeeking Alpha • 09/03/25
Exelixis, Inc. (EXEL) Presents At 2025 Wells Fargo Healthcare Conference (Transcript)Seeking Alpha • 09/03/25
Exelixis vs. Merck: Which Oncology Stock Is a Better Pick as of Now?Zacks Investment Research • 08/25/25
Will Zanzalintinib Ease Out EXEL's Reliance on Cabometyx for Growth?Zacks Investment Research • 08/13/25
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Exelixis, Inc. - EXELGlobeNewsWire • 08/09/25
Cabometyx Sales Miss Mark in Q2: What Does This Mean for EXEL Stock?Zacks Investment Research • 08/05/25
Don't Overlook Exelixis (EXEL) International Revenue Trends While Assessing the StockZacks Investment Research • 08/04/25